https://www.iozk.de/wp-content/uploads/2019/05/Schirrmacher_Vortrag.jpg
1000
1500
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2019-05-22 06:52:582019-07-15 15:46:53Professor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-16 / 2019 May;19(1):460
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-16 / 2019 May;19(1):4602019-05-16 00:00:002020-10-05 10:19:52Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-14 / BMJ Open 2019 05;9(5):e026779
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-14 / BMJ Open 2019 05;9(5):e0267792019-05-14 00:00:002019-05-14 00:00:00Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-02 / Crit. Rev. Oncol. Hematol. 2019 Jul;139:67-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-02 / Crit. Rev. Oncol. Hematol. 2019 Jul;139:67-742019-05-02 00:00:002019-05-02 00:00:00Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-01 / Nat. Rev. Cancer 2019 05;19(5):271-282
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-01 / Nat. Rev. Cancer 2019 05;19(5):271-2822019-05-01 00:00:002019-05-01 00:00:00Targeting cancer vulnerabilities with high-dose vitamin C
